An Open Label Study of CM-AT for the Treatment of Children With Autism

Autism Clinical Trial

Official title:

An Open-Label Extension Study of CM-AT for the Treatment of Children With Autism With All Levels of Fecal Chymotrypsin

Clinical Trial Details — Status: Active, not recruiting

Administrative data

• NCT number: NCT02649959
• Other study ID #: 00104/Open Label-Autism
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: October 2015
• Est. completion date: January 2025

Study information

• Verified date: October 2023
• Source: Curemark
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase III, open label extension study evaluating the continued safety and efficacy of CM-AT in pediatric patients with autism with all levels of fecal chymotrypsin.

Description:

Autism is clearly a significant cause of disability in the pediatric population. Treatment is based on the observation that many children with autism do not digest protein. CM-AT is a proprietary enzyme that is designed as a granulated powder taken three times daily.

Recruitment information / eligibility

• Status: Active, not recruiting
• Enrollment: 405
• Est. completion date: January 2025
• Est. primary completion date: January 2025
• Accepts healthy volunteers: No
• Gender: All
• Age group: 3 Years to 17 Years

Eligibility

Inclusion Criteria:

• Age between 3 and 8 years, inclusive, at the time of signing informed consent/assent in Sponsor 00103 Study

• Completion of the Sponsor's 00103 Study who continue to meet eligibility requirements

• Currently in the 00102 open label study and continue to meet eligibility requirements

• Subjects who initially qualified for 00103 screening, who subsequently failed Baseline entrance criteria for randomization (@Visit 1) Baseline assessment of the ABC eligibility requirement who continue to meet eligibility requirements

• Up to 20 subjects 9-17 years of age who directly enroll into this study, who meet the current Diagnostic and Statistical Manual for Mental Disorders (DSM-IV-TR) diagnostic criteria for Autistic Disorder (AD), screened by the SCQ and confirmed by the ADI-R

Exclusion Criteria:

• Patient weighing < 13kg

• Allergy to porcine products

• Previous sensitization or allergy to trypsin, pancreatin, or pancrelipase

• History of severe head trauma, as defined by loss of consciousness or hospitalization, skull fracture or stroke.

• Seizure within the last year prior to enrollment, or the need for seizure medications either at present or in the past.

• Evidence or history of severe, moderate or uncontrolled systemic disease

• Ongoing dietary restriction for allergy or other reasons except nut allergies. Lactose free is allowable but not dairy free.

• Inability to ingest the study drug / non-compliance with dosing schedule.

• Inability to follow the prescribed dosing schedule.

• Use of any stimulant or non-stimulant medication or medications given for attention deficit hyperactivity disorder (ADHD) must be discontinued 5 days prior to the initial randomized study period.

• Subjects taking an selective serotonin reuptake inhibitor (SSRI) must be on a stable dose for a minimum of 30 days prior to entering the study.

• History of premature birth <35 weeks gestation.

• Prior history of stroke in utero or other in utero insult.

Related Conditions & MeSH terms

• Autism
• Autistic Disorder

Intervention

Drug:
• CM-AT
Single unit does powder of active substance (CM-AT) administered 3 times per day

Locations

Country	Name	City	State
United States	Lovelace Scientific Resources	Albuquerque	New Mexico
United States	Detroit Clinical Research Center, P.C.	Bingham Farms	Michigan
United States	Montefiore Med.Cneter, Autism & Obsessive Compulsive Spectrum Program	Bronx	New York
United States	IMMUNOe Research Centers	Centennial	Colorado
United States	Carolina Clinical Trials, Inc.	Charleston	South Carolina
United States	University of Virginia, Dept. of Psychiatry and Neurobehavioral Sciences	Charlottesville	Virginia
United States	Cleveland Clinic Autism Center	Cleveland	Ohio
United States	Focus Center of Clinical Research	Clinton	Utah
United States	Duke Center For Autism and Brain Development	Durham	North Carolina
United States	Children'S Specialized Hospital	Egg Harbor Township	New Jersey
United States	Neuroscience, Inc	Herndon	Virginia
United States	University of Texas, Houston-Behavioral & Biomedical Sciences	Houston	Texas
United States	Lake Charles Clinical Trials	Lake Charles	Louisiana
United States	Arkansas Children'S Hosp. Research Institute (A.C.H.R.I.)	Little Rock	Arkansas
United States	Vanderbilt Universtiy Med.Center-Treatment&Research Inst. For Asd	Nashville	Tennessee
United States	Yale Child Study Center	New Haven	Connecticut
United States	Research Institute of Deaconess Clinic	Newburgh	Indiana
United States	Segal Institute For Clinical Research	North Miami	Florida
United States	N.R.C. Research Institute	Orange	California
United States	Advent Health -Lake Mary Pediatrics	Orange City	Florida
United States	A.P.G. Research	Orlando	Florida
United States	Southwest Autism Research & Resource Center (S.A.R.R.C.)	Phoenix	Arizona
United States	Carilion Clinic-Virginia Tech, Carilion School of Medicine	Roanoke	Virginia
United States	M.I.N.D. Institute (Univ.of California, Davis)	Sacramento	California
United States	University of California (U.C.S.F.)	San Francisco	California
United States	L.S.U. Health Sciences Center	Shreveport	Louisiana
United States	Richmond Behavioral Associates	Staten Island	New York
United States	Barbara Enright	Toms River	New Jersey
United States	University of Arizona, Pediatrics Multidisciplinary Research Unit	Tucson	Arizona
United States	Clinical Research Center of Nj	Voorhees	New Jersey
United States	Omega Medical Research	Warwick	Rhode Island

Sponsors (1)

Lead Sponsor	Collaborator
Curemark

Country where clinical trial is conducted

United States, 

References & Publications (28)

Arnold GL, Hyman SL, Mooney RA, Kirby RS. Plasma amino acids profiles in children with autism: potential risk of nutritional deficiencies. J Autism Dev Disord. 2003 Aug;33(4):449-54. doi: 10.1023/a:1025071014191. — View Citation

Bailey DB Jr, Raspa M, Olmsted M, Holiday DB. Co-occurring conditions associated with FMR1 gene variations: findings from a national parent survey. Am J Med Genet A. 2008 Aug 15;146A(16):2060-9. doi: 10.1002/ajmg.a.32439. — View Citation

Baio, J. Prevalence of Autism Spectrum Disorders - Autism and Developmental Disabilities Monitoring Network, 14 Sites, United States. (2008), Retrieved from http://www.cdc.gov/mmwr/pdf/ss/ss6103.pdf

Baio, J. Prevalence of Autism Spectrum Disorders - Autism and Developmental Disabilities Monitoring Network, 14 Sites, United States.(2010). Retrieved from http://www.cdc.gov/mmwr/pdf/ss/ss6302.pdf

Balasubramanian MN, Butterworth EA, Kilberg MS. Asparagine synthetase: regulation by cell stress and involvement in tumor biology. Am J Physiol Endocrinol Metab. 2013 Apr 15;304(8):E789-99. doi: 10.1152/ajpendo.00015.2013. Epub 2013 Feb 12. — View Citation

Borowitz D. Update on the evaluation of pancreatic exocrine status in cystic fibrosis. Curr Opin Pulm Med. 2005 Nov;11(6):524-7. doi: 10.1097/01.mcp.0000181474.08058.b3. — View Citation

Buie T, Campbell DB, Fuchs GJ 3rd, Furuta GT, Levy J, Vandewater J, Whitaker AH, Atkins D, Bauman ML, Beaudet AL, Carr EG, Gershon MD, Hyman SL, Jirapinyo P, Jyonouchi H, Kooros K, Kushak R, Levitt P, Levy SE, Lewis JD, Murray KF, Natowicz MR, Sabra A, Wershil BK, Weston SC, Zeltzer L, Winter H. Evaluation, diagnosis, and treatment of gastrointestinal disorders in individuals with ASDs: a consensus report. Pediatrics. 2010 Jan;125 Suppl 1:S1-18. doi: 10.1542/peds.2009-1878C. — View Citation

Cavallini G, Benini L, Brocco G, Riela A, Bovo P, Pederzoli P, Angelini G, Pelle C, Bertelli G, Scuro LA. The fecal chymotrypsin photometric assay in the evaluation of exocrine pancreatic capacity. Comparison with other direct and indirect pancreatic function tests. Pancreas. 1989;4(3):300-4. doi: 10.1097/00006676-198906000-00005. — View Citation

Coutinho AM, Oliveira G, Morgadinho T, Fesel C, Macedo TR, Bento C, Marques C, Ataide A, Miguel T, Borges L, Vicente AM. Variants of the serotonin transporter gene (SLC6A4) significantly contribute to hyperserotonemia in autism. Mol Psychiatry. 2004 Mar;9(3):264-71. doi: 10.1038/sj.mp.4001409. — View Citation

Elsabbagh M, Divan G, Koh YJ, Kim YS, Kauchali S, Marcin C, Montiel-Nava C, Patel V, Paula CS, Wang C, Yasamy MT, Fombonne E. Global prevalence of autism and other pervasive developmental disorders. Autism Res. 2012 Jun;5(3):160-79. doi: 10.1002/aur.239. Epub 2012 Apr 11. — View Citation

Fairclough PD, Hegarty JE, Silk DB, Clark ML. Comparison of the absorption of two protein hydrolysates and their effects on water and electrolyte movements in the human jejunum. Gut. 1980 Oct;21(10):829-34. doi: 10.1136/gut.21.10.829. — View Citation

Ganz ML. The lifetime distribution of the incremental societal costs of autism. Arch Pediatr Adolesc Med. 2007 Apr;161(4):343-9. doi: 10.1001/archpedi.161.4.343. — View Citation

Lecavalier L. An evaluation of the Gilliam Autism Rating Scale. J Autism Dev Disord. 2005 Dec;35(6):795-805. doi: 10.1007/s10803-005-0025-6. — View Citation

Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, Aman MG. A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry. 2009 Nov;48(11):1110-1119. doi: 10.1097/CHI.0b013e3181b76658. — View Citation

Matthews DM. Intestinal absorption of amino acids and peptides. Proc Nutr Soc. 1972 Sep;31(2):171-7. doi: 10.1079/pns19720033. No abstract available. — View Citation

McElhanon BO, McCracken C, Karpen S, Sharp WG. Gastrointestinal symptoms in autism spectrum disorder: a meta-analysis. Pediatrics. 2014 May;133(5):872-83. doi: 10.1542/peds.2013-3995. — View Citation

McPheeters ML, Warren Z, Sathe N, Bruzek JL, Krishnaswami S, Jerome RN, Veenstra-Vanderweele J. A systematic review of medical treatments for children with autism spectrum disorders. Pediatrics. 2011 May;127(5):e1312-21. doi: 10.1542/peds.2011-0427. Epub 2011 Apr 4. — View Citation

Munasinghe SA, Oliff C, Finn J, Wray JA. Digestive enzyme supplementation for autism spectrum disorders: a double-blind randomized controlled trial. J Autism Dev Disord. 2010 Sep;40(9):1131-8. doi: 10.1007/s10803-010-0974-2. — View Citation

Naushad SM, Jain JM, Prasad CK, Naik U, Akella RR. Autistic children exhibit distinct plasma amino acid profile. Indian J Biochem Biophys. 2013 Oct;50(5):474-8. — View Citation

Peacock G, Amendah D, Ouyang L, Grosse SD. Autism spectrum disorders and health care expenditures: the effects of co-occurring conditions. J Dev Behav Pediatr. 2012 Jan;33(1):2-8. doi: 10.1097/DBP.0b013e31823969de. — View Citation

Penn AH, Hugli TE, Schmid-Schonbein GW. Pancreatic enzymes generate cytotoxic mediators in the intestine. Shock. 2007 Mar;27(3):296-304. doi: 10.1097/01.shk.0000235139.20775.7f. — View Citation

Samsam M, Ahangari R, Naser SA. Pathophysiology of autism spectrum disorders: revisiting gastrointestinal involvement and immune imbalance. World J Gastroenterol. 2014 Aug 7;20(29):9942-51. doi: 10.3748/wjg.v20.i29.9942. — View Citation

Schreck KA, Williams K, Smith AF. A comparison of eating behaviors between children with and without autism. J Autism Dev Disord. 2004 Aug;34(4):433-8. doi: 10.1023/b:jadd.0000037419.78531.86. — View Citation

Schreck KA, Williams K. Food preferences and factors influencing food selectivity for children with autism spectrum disorders. Res Dev Disabil. 2006 Jul-Aug;27(4):353-63. doi: 10.1016/j.ridd.2005.03.005. Epub 2005 Jul 25. — View Citation

Tang G, Gudsnuk K, Kuo SH, Cotrina ML, Rosoklija G, Sosunov A, Sonders MS, Kanter E, Castagna C, Yamamoto A, Yue Z, Arancio O, Peterson BS, Champagne F, Dwork AJ, Goldman J, Sulzer D. Loss of mTOR-dependent macroautophagy causes autistic-like synaptic pruning deficits. Neuron. 2014 Sep 3;83(5):1131-43. doi: 10.1016/j.neuron.2014.07.040. Epub 2014 Aug 21. Erratum In: Neuron. 2014 Sep 17;83(6):1482. — View Citation

Wasfy M, Oyofo B, Elgindy A, Churilla A. Comparison of preservation media for storage of stool samples. J Clin Microbiol. 1995 Aug;33(8):2176-8. doi: 10.1128/jcm.33.8.2176-2178.1995. — View Citation

Williams K, Wheeler DM, Silove N, Hazell P. Selective serotonin reuptake inhibitors (SSRIs) for autism spectrum disorders (ASD). Cochrane Database Syst Rev. 2010 Aug 4;(8):CD004677. doi: 10.1002/14651858.CD004677.pub2. — View Citation

Yerys BE, Wallace GL, Sokoloff JL, Shook DA, James JD, Kenworthy L. Attention deficit/hyperactivity disorder symptoms moderate cognition and behavior in children with autism spectrum disorders. Autism Res. 2009 Dec;2(6):322-33. doi: 10.1002/aur.103. — View Citation

* Note: There are 28 references in all — Click here to view all references

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Aberrant Behavioral Checklist: Subscale of Irritability / Agitation (ABC-I) at fecal chymotrypsin (FCT) levels less than or equal to 12.6		Change from Baseline to each post-baseline visit, through study completion Week 72.
Secondary	Aberrant Behavior Checklist: Subscale of Lethargy / Social Withdrawal (ABC-L) at fecal chymotrypsin (FCT) levels less than or equal to 12.6		Change from Baseline to each post-baseline visit, through study completion Week 72.